Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
暂无分享,去创建一个
Rajyalakshmi Luthra | K. Patel | F. Ravandi | L. Medeiros | Deqin Ma | R. Luthra | A. Paladugu | Farhad Ravandi | B. Barkoh | Deqin Ma | Bedia A Barkoh | L Jeffrey Medeiros | Keyur P Patel | Abhaya Paladugu
[1] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Döhner,et al. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. , 2008, Seminars in oncology.
[3] O. Abdel-Wahab,et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. , 2010, Cancer research.
[4] S. Scholl,et al. Clinical implications of molecular genetic aberrations in acute myeloid leukemia , 2009, Journal of Cancer Research and Clinical Oncology.
[5] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[6] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[7] A. Marchetti,et al. IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors , 2009, Human mutation.
[8] N. Yoo,et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers , 2009, International journal of cancer.
[9] F. Ferrara,et al. Clinically useful prognostic factors in acute myeloid leukemia. , 2008, Critical reviews in oncology/hematology.
[10] A. Green,et al. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. , 2010, The New England journal of medicine.
[11] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[12] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[13] Pu Zhang,et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.
[14] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[15] V. Velculescu,et al. Mutant metabolic enzymes are at the origin of gliomas. , 2009, Cancer research.
[16] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[17] L. Medeiros,et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. , 2006, American journal of clinical pathology.
[18] H. Mikawa,et al. Metabolic basis for differential glutamine requirements of human leukemia cell lines , 1990, Journal of cellular physiology.
[19] S. Serrano,et al. KLF6 and TP53 mutations are a rare event in prostate cancer: distinguishing between Taq polymerase artifacts and true mutations , 2008, Modern Pathology.
[20] M. Fey,et al. Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.
[21] K. Wagner,et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[23] P. Kleihues,et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.
[24] C. Hoogenraad,et al. Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.
[25] A. Aventín,et al. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. , 2006, Haematologica.
[26] E. Gottlieb,et al. IDH1 mutations in gliomas: when an enzyme loses its grip. , 2010, Cancer cell.
[27] H. Koeppen,et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.
[28] I. Bernstein,et al. Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study , 2010, Leukemia.
[29] Tak W. Mak,et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.
[30] C. Thompson,et al. Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.
[31] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[32] K. Döhner,et al. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia , 2009, Current opinion in hematology.
[33] J. Weinberg,et al. Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. , 1989, Blood.
[34] C. Bloomfield,et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.
[35] L. Medeiros,et al. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. , 2004, American journal of clinical pathology.
[36] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[37] Jih-Luh Tang,et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. , 2010, Blood.
[38] Guido Marcucci,et al. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics , 2005, Current opinion in hematology.
[39] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.